Guardant Health Inc.(GH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GH Guardant Health Inc.

休市中 07-02 16:00:00 EDT

167.98

-2.79

-1.63%

盘后167.98

+0.000.00%

19:58 EDT

最高171.99	最低166.74	成交量345.53万
今开171.96	昨收170.77	日振幅3.07%
总市值222.70亿	流通市值213.33亿	总股本1.33亿
成交额5.83亿	换手率2.72%	流通股本1.27亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GH","market":"US","secType":"STK","nameCN":"Guardant Health Inc.","latestPrice":167.98,"timestamp":1783022400000,"preClose":170.77,"halted":0,"volume":3455312,"hourTrading":{"tag":"盘后","latestPrice":167.98,"preClose":167.98,"latestTime":"19:58 EDT","volume":253937,"amount":42651125.19,"timestamp":1783036699784,"change":0,"changeRate":0,"amplitude":0.019416},"delay":0,"changeRate":-0.016337764244305324,"floatShares":127000000,"shares":132573424,"eps":-3.404949,"marketStatus":"休市中","change":-2.79,"latestTime":"07-02 16:00:00 EDT","open":171.955,"high":171.99,"low":166.74,"amount":583142882.17584,"amplitude":0.030743,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.404949,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":170.77,"preHourTrading":{"tag":"盘前","latestPrice":171.53,"preClose":170.77,"latestTime":"09:28 EDT","volume":1244,"amount":212784.17228,"timestamp":1782998881039,"change":0.76,"changeRate":0.00445,"amplitude":0.025044},"postHourTrading":{"tag":"盘后","latestPrice":167.98,"preClose":167.98,"latestTime":"19:58 EDT","volume":253937,"amount":42651125.19,"timestamp":1783036699784,"change":0,"changeRate":0,"amplitude":0.019416},"volumeRatio":0.5060588743784289,"impliedVol":0.613,"impliedVolPercentile":0.4821},"requestUrl":"/m/hq/s/GH","defaultTab":"news","newsList":[{"id":"1125693974","title":"异动解读｜Guardant Health盘中上涨7.47%，伯恩斯坦看好ADLT定价资格带来营收上行空间","url":"https://stock-news.laohu8.com/highlight/detail?id=1125693974","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125693974?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:01","pubTimestamp":1782914487,"startTime":"0","endTime":"0","summary":"7月1日，Guardant Health盘中上涨7.47%，报161.78美元/股，成交额1.96亿美元。消息面上，伯恩斯坦发布最新研报，给予公司\"跑赢大市\"评级及175美元目标价，指出G360 ADLT定价资格将带来可观营收上行空间，且尚未充分反映在市场一致预期中。叠加近期Guardant360 Liquid CDx获FDA批准及Shield血液检测纳入美国癌症协会筛查指南等多重催化，市场情绪持续升温。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169680987","title":"异动解读｜Guardant Health盘前上涨5.35%，伯恩斯坦看好ADLT定价资格带来营收上行空间","url":"https://stock-news.laohu8.com/highlight/detail?id=1169680987","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169680987?lang=zh_cn&edition=full","pubTime":"2026-07-01 21:23","pubTimestamp":1782912206,"startTime":"0","endTime":"0","summary":"7月1日，Guardant Health盘前上涨5.35%，报158.05美元/股，成交额67.2万美元。消息面上，伯恩斯坦在最新研报中给予该公司\"跑赢大市\"评级及175美元目标价，指出G360 ADLT定价资格将带来可观营收上行空间，且尚未充分反映在市场一致预期中。伯恩斯坦对公司2027年盈利预测较一致预期高6.6%，2028年高12.2%，并认为市场明显低估其毛利率改善潜力，向NovaSeq X平台切换预计为全年带来350至550个基点的正面影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115063321","title":"异动解读｜Guardant Health盘中上涨5.08%，多重利好催化延续强势","url":"https://stock-news.laohu8.com/highlight/detail?id=1115063321","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115063321?lang=zh_cn&edition=full","pubTime":"2026-06-27 00:36","pubTimestamp":1782491812,"startTime":"0","endTime":"0","summary":"6月27日，Guardant Health盘中上涨5.08%，报150.2美元/股，成交额1.77亿美元。近期多重利好共振持续推动股价走强。消息面上，RBC Capital Markets于6月12日首次覆盖并给予\"跑赢大盘\"评级及185美元目标价，指出美国仅约25%的转移性癌症患者接受基因组分析，公司作为市场领导者最受益于行业渗透扩大。此外，Guardant360 CDx于6月11日获FDA批准作为非小细胞肺癌伴随诊断，叠加一季度业绩大超预期及全年收入指引上调至13.0亿-13.2亿美元，多重催化共振推动股价连续走高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180460572","title":"异动解读｜Guardant Health盘中上涨5.05%，多重利好催化延续涨势","url":"https://stock-news.laohu8.com/highlight/detail?id=1180460572","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180460572?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:31","pubTimestamp":1782397862,"startTime":"0","endTime":"0","summary":"6月25日，Guardant Health盘中上涨5.05%，报143.31美元/股，成交额7875.13万美元。消息面上，RBC Capital Markets于6月12日首次覆盖并给予\"跑赢大盘\"评级及185美元目标价，指出美国仅约25%的转移性癌症患者接受基因组分析，公司作为市场领导者最受益于行业渗透扩大。此外，6月11日Guardant360 CDx获FDA批准作为非小细胞肺癌伴随诊断，叠加一季度业绩大超预期及全年收入指引上调至13.0亿-13.2亿美元，多重催化共振推动股价延续强势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123755623","title":"异动解读｜Guardant Health盘中上涨5.22%，报137.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1123755623","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123755623?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:35","pubTimestamp":1782311704,"startTime":"0","endTime":"0","summary":"6月24日，Guardant Health盘中上涨5.22%，报137.51美元/股，成交额9828.98万美元。Guardant Health所在的保健护理服务行业中，个股中，BillionToOne涨4.97%，奎斯特诊疗涨2.15%，西维斯健康跌1.45%，Hims & Hers Health跌1.93%，信诺保险跌2.68%。Guardant Health是一家领先的精密肿瘤学公司，致力于通过使用其专有血液测试、大量数据集和高级分析来帮助全球征服癌症。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173869903","title":"Guardant Health宣布Guardant360 Cdx获FDA批准，作为勃林格殷格翰Hernexeos®的伴随诊断","url":"https://stock-news.laohu8.com/highlight/detail?id=1173869903","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173869903?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:07","pubTimestamp":1781179639,"startTime":"0","endTime":"0","summary":"Guardant Health Inc. 宣布，其Guardant360 Cdx检测产品已获得美国食品药品监督管理局的批准，将作为勃林格殷格翰公司靶向药物Hernexeos的伴随诊断使用。此次批准意味着，临床医生现在可以使用Guardant Health的液体活检技术，通过简单的血液检测来确定患者是否适合接受Hernexeos治疗。对于Guardant Health而言，此次FDA批准是其产品商业化进程中的一个重要里程碑，有望进一步巩固其在液体活检和伴随诊断市场的地位。Hernexeos是勃林格殷格翰开发的一款针对特定基因突变的新型抗癌药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","GH","BK4196","BK4585","BK4551","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171389861","title":"Evercore ISI将Guardant Health评级从“符合预期”上调至“跑赢大盘”，目标价大幅提升至160美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171389861","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171389861?lang=zh_cn&edition=full","pubTime":"2026-06-02 18:05","pubTimestamp":1780394728,"startTime":"0","endTime":"0","summary":"Evercore ISI的分析师将Guardant Health Inc.的股票评级从“符合预期”上调至“跑赢大盘”，同时将其目标价从95美元大幅调升至160美元。此举反映了该机构对该公司前景的显著看好。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4196","BK4535","BK4551","BK4588","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184911159","title":"异动解读｜Guardant Health盘前上涨5.87%，Shield血液测试纳入美国癌症协会筛查指南","url":"https://stock-news.laohu8.com/highlight/detail?id=1184911159","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184911159?lang=zh_cn&edition=full","pubTime":"2026-05-28 16:35","pubTimestamp":1779957302,"startTime":"0","endTime":"0","summary":"5月28日，Guardant Health盘前上涨5.87%，报127.78美元/股，成交额8.48万美元。消息面上，公司宣布其Shield血液测试已被纳入美国癌症协会更新的结直肠癌筛查指南，该指南建议将Shield作为拒绝或未完成粪便检测及视觉检查筛查的患者的替代选项，进一步验证了公司在液体活检领域的临床价值。此前5月21日，公司另一款Guardant360 Liquid CDx液体活检测试获美国FDA批准，作为非小细胞肺癌和结直肠癌多种疗法的伴随诊断工具，基因组覆盖范围较此前获批版本扩大100倍。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115365028","title":"异动解读｜Guardant Health盘中上涨5.26%，Shield血液测试纳入美国癌症协会筛查指南","url":"https://stock-news.laohu8.com/highlight/detail?id=1115365028","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115365028?lang=zh_cn&edition=full","pubTime":"2026-05-28 00:47","pubTimestamp":1779900443,"startTime":"0","endTime":"0","summary":"5月28日，Guardant Health盘中上涨5.26%，报126.155美元/股，成交额1.9亿美元。消息面上，公司宣布其Shield血液测试已被纳入美国癌症协会更新的结直肠癌筛查指南。该指南建议将Shield作为拒绝或未完成粪便检测及视觉检查筛查的患者的替代选项，进一步验证了公司在液体活检领域的临床价值。Guardant Health是一家领先的精密肿瘤学公司，致力于通过使用其专有血液测试、大量数据集和高级分析来帮助全球征服癌症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158523251","title":"异动解读｜Guardant Health盘前下跌8.48%，报118.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1158523251","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158523251?lang=zh_cn&edition=full","pubTime":"2026-05-22 19:03","pubTimestamp":1779447799,"startTime":"0","endTime":"0","summary":"5月22日，Guardant Health盘前下跌8.48%，报118.01美元/股，成交额3.69万美元。Guardant Health所在的保健护理服务行业中，个股中，西维斯健康跌0.09%，Hims & Hers Health Inc.跌0.46%，信诺保险跌0.46%，达维塔保健跌0.01%，BrightSpring Health Services Inc.涨0.02%。Guardant Health是一家领先的精密肿瘤学公司，致力于通过使用其专有血液测试、大量数据集和高级分析来帮助全球征服癌症。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193885123","title":"异动解读｜Guardant Health盘中上涨5.01%，液体活检测试获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1193885123","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193885123?lang=zh_cn&edition=full","pubTime":"2026-05-21 23:29","pubTimestamp":1779377346,"startTime":"0","endTime":"0","summary":"5月21日，Guardant Health盘中上涨5.01%，报120.73美元/股，成交额1.05亿美元。消息面上，公司宣布美国食品药品监督管理局已批准其Guardant360 Liquid CDx液体活检测试，作为非小细胞肺癌和结直肠癌多种疗法的伴随诊断工具。该测试通过单次抽血即可整合基因组和表观基因组分析，检测循环肿瘤DNA的灵敏度更高，基因组覆盖范围较此前获批的Guardant360 CDx扩大100倍，且可在七天内交付结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145198986","title":"异动解读 | 获多家投行上调目标价，Guardant Health盘前大涨5.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145198986","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145198986?lang=zh_cn&edition=full","pubTime":"2026-05-08 20:55","pubTimestamp":1778244912,"startTime":"0","endTime":"0","summary":"Guardant Health Inc. (GH) 今日盘前股价大幅上涨5.68%，引起了市场的关注。消息面上，根据路透报道，多家华尔街投行在今日的研究报告中上调了Guardant Health的目标股价。其中，摩根大通将目标价从130美元上调至135美元，道明考恩也将目标价从120美元上调至127美元。分析师上调目标价通常被视为对公司前景的积极看法，这可能是推动股价在盘前交易时段上涨的主要原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167082470","title":"Guardant Health Inc. 具备有利条件拓展癌症筛查覆盖范围并推动长期价值创造","url":"https://stock-news.laohu8.com/highlight/detail?id=1167082470","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167082470?lang=zh_cn&edition=full","pubTime":"2026-05-08 04:29","pubTimestamp":1778185781,"startTime":"0","endTime":"0","summary":"Guardant Health Inc. 正处于有利地位，有望进一步扩大其在癌症筛查领域的影响力，并为实现长期价值创造奠定坚实基础。\n该公司凭借其前沿的技术平台和创新的检测解决方案，在癌症早期筛查市场展现出强大的增长潜力。通过持续拓展其产品与服务范围，Guardant Health 致力于提升癌症检测的可及性和准确性，从而为患者带来更佳的健康结局。\n展望未来，Guardant Health 的战略布局将专注于深化市场渗透，并通过科技创新驱动业务增长。公司管理层对实现可持续的长期价值充满信心，并将继续执行其既定的发展蓝图。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","GH","BK4585","BK4588","BK4535","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169313504","title":"Guardant Health获FDA批准Guardant360® Cdx作为Arvinas与辉瑞Veppanu（Vepdegestrant）的伴随诊断工具 适用于携带ESR1突变的ER+/HER2-晚期乳腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1169313504","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169313504?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:05","pubTimestamp":1777896322,"startTime":"0","endTime":"0","summary":"Guardant Health公司宣布，其Guardant360 Cdx液体活检产品已获得美国食品药品监督管理局的批准，可作为Arvinas与辉瑞共同开发的Veppanu的伴随诊断工具。该批准专门针对携带ESR1突变的雌激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌患者群体。此次获批意味着临床医生能够通过Guardant360 Cdx这一血液检测技术，精准识别出最可能从Veppanu靶向治疗中获益的患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4588","BK4585","GH","BK4535","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112485703","title":"Guardant Health与Nuvalent达成多年战略合作 将基于Guardant Infinity™平台开发伴随诊断并支持靶向癌症疗法商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=1112485703","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112485703?lang=zh_cn&edition=full","pubTime":"2026-04-30 20:05","pubTimestamp":1777550751,"startTime":"0","endTime":"0","summary":"Guardant Health Inc.宣布与生物制药公司Nuvalent建立为期多年的战略合作伙伴关系。双方将依托Guardant Health的Guardant Infinity液体活检平台，共同开发创新伴随诊断方案，为Nuvalent研发的靶向癌症疗法提供商业化支持。此次合作将聚焦于推动精准医疗发展，通过Guardant Health先进的液体活检技术加速Nuvalent肿瘤靶向药物的临床开发进程。Guardant Infinity平台能够通过血液样本实现全面基因组分析，为个体化治疗方案提供关键数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4588","BK4551","BK4585","BK4535","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162940662","title":"财报前瞻 ｜Guardant Health Inc.本季度营收预计增46.86%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1162940662","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162940662?lang=zh_cn&edition=full","pubTime":"2026-04-30 09:49","pubTimestamp":1777513752,"startTime":"0","endTime":"0","summary":"Guardant Health Inc.将于2026年05月07日发布最新季度财报，市场关注基因液体活检与生物制药合作的收入动能及亏损收窄进展。一致预期显示，Guardant Health Inc.本季度营收预计为2.79亿美元，同比增46.86%；调整后每股收益预计为-0.76美元，同比改善7.93%；息税前利润预计为-9,957.37万美元，同比改善6.48%。近期多家机构对Guardant Health Inc.的短期业绩持建设性态度，观点以看多为主，核心依据在于营收同比增长预期高达46.86%以及EBIT与EPS的同比改善区间。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜Guardant Health Inc.本季度营收预计增46.86%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158545386","title":"Guardant Health旗下Infinityai真实世界证据支持Enhertu®在日本获批用于经治HER2阳性转移性实体瘤患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1158545386","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158545386?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:10","pubTimestamp":1774872616,"startTime":"0","endTime":"0","summary":"Guardant Health公司宣布，其Infinityai真实世界证据研究数据已成功支持靶向药物Enhertu®在日本获得监管批准，该药物将用于治疗既往接受过治疗的HER2阳性转移性实体瘤患者。这一进展标志着真实世界证据在加速创新疗法审批过程中的重要价值得到进一步验证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","GH","BK4585","BK4196","BK4588","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160113114","title":"Guardant Health携手宏利在亚洲多市场推出Shield多癌种检测产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1160113114","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160113114?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:35","pubTimestamp":1773664512,"startTime":"0","endTime":"0","summary":"Guardant Health Inc.与宏利达成合作，正式在亚洲多个市场推出其创新产品——Shield多癌种早期检测测试。\n此次合作标志着Guardant Health在扩大其癌症筛查技术全球可及性方面迈出重要一步。通过利用Guardant Health先进的液体活检技术，Shield测试旨在通过简单血液样本实现对多种癌症类型的早期筛查。\n这一举措有望为亚洲地区患者提供更便捷、高效的癌症早期检测方案，从而提升癌症防治水平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4535","GH","BK4588","BK4585","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120663348","title":"宏利金融与Guardant Health达成独家合作，将Shield多癌种早筛检测引入亚洲市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1120663348","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120663348?lang=zh_cn&edition=full","pubTime":"2026-03-16 11:01","pubTimestamp":1773630071,"startTime":"0","endTime":"0","summary":"宏利金融宣布与Guardant Health Inc.达成独家合作伙伴关系，双方将共同向亚洲地区客户推广Shield多癌种早期检测服务。此次合作旨在通过前沿的癌症筛查技术，为亚洲客户提供更全面的健康管理解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4585","BK4196","GH","BK4588","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185436235","title":"财报前瞻｜Guardant Health Inc.营收预计强劲增长，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1185436235","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185436235?lang=zh_cn&edition=full","pubTime":"2026-02-12 10:24","pubTimestamp":1770863073,"startTime":"0","endTime":"0","summary":"Guardant Health Inc.将于2026年02月19日发布业绩，市场共识预计营收延续高增，亏损率收窄，核心产品渗透扩大成看点。公司目前主营业务亮点在于肿瘤学检测业务，受益于Guardant360与TissueNext在医院端与生物制药客户渗透，带动流水扩大。来自机构的最新观点更偏向看多阵营，占比高于看空观点。某些华尔街机构指出，“随着生物制药合作订单的稳定落地与核心检测项目扩容，Guardant Health Inc.的收入增长确定性较强，若指引印证高增与费用纪律，股价具备进一步修复空间。”","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Guardant Health Inc.营收预计强劲增长，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.guardanthealth.com","stockEarnings":[{"period":"1week","weight":0.1752},{"period":"1month","weight":0.2905},{"period":"3month","weight":0.7903},{"period":"6month","weight":0.6511},{"period":"1year","weight":2.3475},{"period":"ytd","weight":0.6446}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Guardant Health, Inc.于2011年12月在特拉华州注册成立。该公司是一家领先的精密肿瘤学公司，致力于通过使用其专有血液测试，大量数据集和高级分析来帮助全球征服癌症。他们利用先进的血液和组织检测、真实世界数据和人工智能分析，提供关于疾病驱动因素的关键见解，从而变革患者护理。他们的检测有助于改善各个阶段的治疗效果，包括早期癌症筛查、早期癌症复发监测以及晚期癌症患者的治疗方案选择。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.071093},{"month":2,"riseRate":0.25,"avgChangeRate":0.034152},{"month":3,"riseRate":0.5,"avgChangeRate":-0.022808},{"month":4,"riseRate":0.375,"avgChangeRate":-0.022604},{"month":5,"riseRate":0.625,"avgChangeRate":0.118443},{"month":6,"riseRate":0.75,"avgChangeRate":0.091261},{"month":7,"riseRate":0.75,"avgChangeRate":0.059991},{"month":8,"riseRate":0.571429,"avgChangeRate":0.08346},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.065825},{"month":10,"riseRate":0.285714,"avgChangeRate":0.030366},{"month":11,"riseRate":0.75,"avgChangeRate":0.130427},{"month":12,"riseRate":0.5,"avgChangeRate":-0.066498}],"exchange":"NASDAQ","name":"Guardant Health Inc.","nameEN":"Guardant Health Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Guardant Health Inc.(GH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Guardant Health Inc.(GH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Guardant Health Inc.,GH,Guardant Health Inc.股票,Guardant Health Inc.股票老虎,Guardant Health Inc.股票老虎国际,Guardant Health Inc.行情,Guardant Health Inc.股票行情,Guardant Health Inc.股价,Guardant Health Inc.股市,Guardant Health Inc.股票价格,Guardant Health Inc.股票交易,Guardant Health Inc.股票购买,Guardant Health Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Guardant Health Inc.(GH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Guardant Health Inc.(GH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}